Heron Therapeutics, Inc. (HRTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Heron Therapeutics, Inc. on November 4, 2024. The report discloses corporate governance changes and regulatory disclosures effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on non-financial corporate events.
Material Changes
- Board Appointment: The Board of Directors appointed Michael Kaseta as a new director on November 4, 2024.
- Term Details: Mr. Kaseta's term expires at the Company's 2025 annual meeting of stockholders or until his successor is elected, qualified, or until earlier death, resignation, or removal.
- Committee Assignments: No committee appointments have been made for Mr. Kaseta at this time.
Guidance, Outlook, and Management Commentary
- Compensation: Mr. Kaseta will receive compensation in accordance with the Company's standard program for non-employee directors, as detailed in the definitive proxy statement filed on April 29, 2024.
- Indemnification: Mr. Kaseta will enter into the Company's standard Director Indemnification Agreement, the full text of which will be filed as an exhibit to the 2024 Form 10-K.
- Related Disclosure: A press release regarding these matters was issued on November 4, 2024, and is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the specific compensation amounts for non-employee directors in the April 29, 2024, Schedule 14A proxy statement.
- Review the full text of the Director Indemnification Agreement once filed as an exhibit to the 2024 Form 10-K.
- Monitor future announcements for Mr. Kaseta's specific committee assignments.
- Confirm the date of the 2025 annual meeting of stockholders to determine the exact expiration of the current term.